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ngiography with its inherent limitations might not reliably
redict whether a stenosis induces ischemia. It is well-
ocumented that the angiographic assessment of a coronary
tenosis correlates poorly with its physiologic significance.
ractional flow reserve (FFR) is an index of the physiolog-
cal significance of a coronary stenosis and is defined as the
atio of maximal blood flow in a stenotic artery to normal
aximal flow. The measurement of FFR by a sensor wire
See page 357
as been validated as a technique for the functional assess-
ent of coronary stenoses. Validation studies of FFR
easurements have demonstrated a strong correlation be-
ween the FFR and stress tests. The information provided
y FFR is similar to that obtained with myocardial perfu-
ion studies but is more specific, and FFR has a better
patial resolution, because every artery or segment is ana-
yzed separately. The recommended diagnostic approach in
atients with a coronary stenosis includes a number of
oninvasive cardiac stress imaging techniques; however, it is
ell-known that, in patients with multivessel disease, such
echniques are limited in their ability to allocate wall motion
r perfusion defects to a “culprit” stenosis.
Pijls et al. (1) demonstrated that 5-year outcome after
eferral of percutaneous coronary intervention of interme-
iate coronary stenoses, on the basis of an FFR cut-point of
.75, was excellent. In addition, they demonstrated that the
isk of cardiac death or myocardial infarction was not
ecreased by stenting. These findings are further substanti-
ted by the fact that deferral of revascularization of angio-
Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-t
ions or the American College of Cardiology.
From the University of Cincinnati College of Medicine, Cincinnati, Ohio.raphically severe but physiologically insignificant stenoses
as associated with a favorable outcome and spontaneous
esolution of symptoms. Deferring percutaneous coronary
ntervention in nonischemic stenotic lesions as assessed by
FR is associated with an annual rate of death or myocardial
nfarction of approximately 1% in patients with single-vessel
oronary artery disease, which is lower than the rate after
outine stenting. It is worth noting that, even in the era of
rug-eluting stents (DES), stenting of a nonsignificant
oronary artery stenosis has no prognostic advantage.
Normal epicardial coronary arteries provide no resistance
o blood flow, not even during maximum hyperemia. There-
ore, optimum coronary stenting should at least result in the
isappearance of any hyperemic pressure drop within the
espective coronary segment. The measurement of FFR has
een proposed as a technique for optimizing the stent
esults. Indeed, the elimination of any trans-stenotic hyper-
mic gradient after stenting correlates well with optimal
tent deployment on the basis of intravascular ultrasound
IVUS) criteria. Abnormal FFR identifies both residual
yperemic pressure gradient and abnormal resistance across
he stented segment and in the adjacent parts of the vessel.
n this respect, Pijls et al. (2) conducted a multicenter
are-metal stent (BMS) FFR registry in 750 patients to
nvestigate the correlation between FFR measured after
tent implantation and major adverse cardiac events, includ-
ng the need for target vessel revascularization during the 6
onths after implantation. This study demonstrated that
easurement of FFR immediately after stent implantation
s a strong independent predictor of the event rates such as
eath, myocardial infarction, or need for repeat revascular-
zation of the target vessel within 6 months. Likewise, the
tudy demonstrated that the higher the FFR, the lower the
vent rate such that, in 36% of the patients that FFR
ormalized (FFR 0.95), event rate was 4.9%. In 32% of
he patients, post-stent FFR was between 0.90 and 0.95,
nd event rate was 6.2%. In 32% of patients, post-stent FFR
as0.90, and event rate was 20.3%. In 6% of the patients,
FR was 0.80, and event rate was 29.5% (p  0.001).
The study reported by Samady et al. (3) in this issue of
ACC: Cardiovascular Interventions, is a post hoc analysis of
86 patients derived from the BMS FFR registry that was
riginally reported in 750 patients (2). Because the BMS
egistry demonstrated that an FFR0.90 after stenting was
ssociated with a low event rate of 6%, Samady et al. (3)
ought to determine whether variables such as baseline FFR,
tent diameter, and stent length would predict a post-stent
FR of 0.90. In this context, Samady et al. (3) demon-
trated that a baseline FFR0.70 compared with a baseline
FR 0.70, after deployment of a 3.0-mm-diameter stent
n patients with a coronary artery stenosis, would yield a
igher likelihood of achieving an FFR0.90 (77% vs. 63%,
espectively; p 0.05). Likewise, Samady et al. (3) reported
hat a baseline FFR 0.50 compared with a baseline FFR
r
d
a
r
t
r
i
0
r
v
I
s
w
p
p

t
a
e
s
F
w
h
c

D
c
a
d
a
g
p
f
s
t
p
m
t
i
c
m
t
s
o
s
d
o
n
n
w
i
s
p
i
i
t
a
s
d
p
t
p
a
n
b
fi
s
l
F
R
P
D
C
C
R
1
2
3
4
5
6
7
8
9
K
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 2 , N O . 4 , 2 0 0 9
A P R I L 2 0 0 9 : 3 6 4 – 5
Leesar
Editorial Comment
365anging from 0.50 to 0.70 and a baseline FFR 0.70, after
eployment of a stent with a diameter 3.0 mm, was
ssociated with a higher event rate (40% vs. 15%, and 13%,
espectively; p 0.05). Furthermore, Samady et al. reported
hat event rates in patients with a stent diameter 3.0 mm,
egardless of baseline FFR, were 10% with a BMS.
The authors are to be commended for their vigilance in
dentifying the predictors of post-stent FFR cut-point of
.90. Notably, the study is a post hoc analysis of a large
egistry with all its inherent limitations and requires further
alidation, but the data have important clinical implications.
n this respect, the results suggest that baseline FFR and
tent diameter would usher in a decision-making strategy
ith respect to judicious use of a BMS versus a DES. In
articular, the aforementioned data indicate that, among
atients with a stent diameter 3.0 mm, event rates were
10% with a BMS, which is similar to that of DES; thus,
his would potentially circumvent the need for a DES. In
ddition, the data indicate that patients with a stent diam-
ter of 3.0 mm and baseline FFR 0.70 would have a
ignificant likelihood of achieving an optimal post-stent
FR of 0.90 with a BMS. Along the same line, patients
ith a stent diameter of 3.0 mm and FFR 0.70 would
ave an acceptable event rate of 13% with a BMS. In
ontrast, patients with a stent diameter 3.0 mm and FFR
0.50 would have a high event rate with a BMS.
In recent years, there has been an explosion in the use of
ES, but concerns have been raised about the possible in-
reased incidence of stent thrombosis with DES. A meta-
nalysis of all randomized trials comparing DES with BMS
emonstrated similar mortality rates (4). One trial even showed
n incidence of late stent thrombosis of 1.4% in the DES
roup versus 0.8% in the BMS group (5). Nevertheless, certain
atient subsets might be well-served with the use of a BMS, if
requency of restenosis can be predicted to be low by FFR or
tent diameter. In addition, multiple studies have shown that
he single most important predictor of stent thrombosis is the
remature discontinuation of antiplatelet therapy, with a dra-
atic increase in stent thrombosis seen in patients taken off
herapy (6). It is of paramount importance that before stent
mplantation, all patients be evaluated for their ability to
ontinuously receive and tolerate dual antiplatelet therapy.
There are several potential clinical implications for measure-
ents of FFR before and after stenting. First, it is well known
hat angiography is limited in defining the significance of
tenosis; therefore, the measurement of FFR might potentially
bviate the need for stenting. Second, it is tempting to
peculate that patients with a baseline FFR 0.70, stent
iameter of 3.0 mm, and short lesion length might achieve an
ptimal post-stent FFR of 0.90, and thus DES might not be
eeded. Furthermore, if such a patient would require biopsy or
oncardiac surgery, clopidogrel therapy could be discontinued
ithin 4 weeks of stenting. Third, angiography is a rather
naccurate tool for evaluating the result of stenting, as demon- ntrated by IVUS. In this respect, incomplete stent deployment,
rotruding struts, or plaque shift at the entry or exit of the stent
s often not recognized by angiography but might result in early
n-stent restenosis (7). Such abnormalities can often be de-
ected by the persistence of a hyperemic pressure gradient
cross the stented segment (8). Therefore, it is likely that
everal patients with restenosis in fact had suboptimal stent
eployment not detected by angiography. Finally, coronary
ressure measurement not only reveals an abnormal conduc-
ance within the stented segment but also indicates increased
laque accumulation in the remaining part of the coronary
rtery, contributing to decreased FFR and worst outcome (9).
The results of the aforementioned studies underscore the
eed for further prospective studies to assess the impact of
aseline FFR, stent diameter, and stent length in predicting
nal FFR after stenting and to address whether additional
trategies, such as performing IVUS or high-pressure bal-
oon inflation after stenting in the setting of suboptimal
FR, would translate into improved outcome.
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